Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

BACKGROUND: In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopalan, Krithika, Trueman, David, Crowe, Lydia, Squirrell, Daniel, Loebel, Antony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901121/
https://www.ncbi.nlm.nih.gov/pubmed/27067724
http://dx.doi.org/10.1007/s40273-016-0405-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901121/
https://www.ncbi.nlm.nih.gov/pubmed/27067724
http://dx.doi.org/10.1007/s40273-016-0405-0

Ejemplares similares